Blood Pressure Pill Shows Promise in Enhancing Cancer Treatment Efficacy

An inexpensive, FDA-approved blood pressure medication, telmisartan, may significantly improve outcomes for cancer patients when combined with specific therapies. This finding stems from recent preclinical research conducted by scientists at Dartmouth Health in New Hampshire.

Telmisartan is currently prescribed to manage hypertension and lower the risk of heart attack and stroke in eligible patients. However, the new study indicates it can also amplify the effectiveness of olaparib, a cancer treatment known as a PARP inhibitor.

Mechanism Behind Enhanced Cancer Cell Damage

In laboratory and animal models, researchers observed that telmisartan causes greater damage to the DNA within cancer cells. This increased damage aids the immune system in identifying and subsequently attacking specific types of tumors.

Lead study author Dr. Tyler J. Curiel noted the significance of the findings. "This study shows that a common, safe, tolerable, convenient and inexpensive drug may significantly improve how well an important class of cancer therapies works," he stated in a release.

Immune Activation Key to Combination Success

The combination of telmisartan and olaparib was found to increase the production of type I interferons. These molecules are crucial as they help the body's immune system recognize and target cancerous cells.

Dr. Curiel explained that this immune activation appears to be the primary reason the drug pairing is so effective. Furthermore, telmisartan was associated with lower levels of PD-L1, a protein utilized by tumor cells to evade immune detection.

Broader Implications for Cancer Therapy

Telmisartan belongs to the class of angiotensin II receptor blockers (ARBs). Importantly, other drugs in this class did not exhibit the same anti-cancer properties observed with telmisartan.

Dr. Curiel elaborated on the drug's potential: "Telmisartan has several distinct anti-cancer effects that, together with targeted therapy, could make tumors more responsive to distinct types of treatments." He added that while the study focused on PARP inhibitors, data also supports telmisartan improving efficacy across other chemotherapy classes and immunotherapies via related mechanisms.

The detailed findings were officially published in the Journal for ImmunoTherapy of Cancer.

Expert Commentary and Study Limitations

Dr. Joshua G. Cohen, medical director of the Gynecologic Cancer Program at City of Hope Orange County, commented on the results, noting past concerns about ARBs increasing cancer risk have been alleviated by large studies confirming their safety.

However, Dr. Cohen stressed the current limitations of the research. "At this stage, the idea is still very early in development, and the evidence comes primarily from laboratory studies, not studies in people," he told Fox News Digital.

  • The research relied heavily on laboratory and animal models, lacking human patient data.
  • Efficacy may be lower in cancers lacking specific DNA defects targeted by the combination.
  • Long-term outcomes or survival data resulting from this combination are currently unavailable.

Dr. Cohen advised that patients should consult their care team regarding the safety and efficacy of combining these medications for their specific situation.

Next Steps: Ongoing Clinical Trials

Researchers at Dartmouth are actively moving this research forward into human testing. Two clinical trials are currently underway to assess telmisartan's effect in patients.

One trial is investigating the combination therapy in men with advanced prostate cancer that is no longer responding to hormone therapy. A second trial, focusing on ovarian cancer resistant to platinum-based chemotherapy, has recently begun enrolling participants.

Dr. Curiel expressed optimism about the ongoing work. "Our goal is to determine whether this combination approach can help more patients benefit from greater effectiveness of PARP inhibitors and other cancer treatment classes and potentially overcome resistance to these drugs," he concluded. Telmisartan is generally considered safe and well-tolerated based on its established clinical history.